360
Participants
Start Date
January 1, 2026
Primary Completion Date
December 1, 2028
Study Completion Date
December 1, 2029
Bismuth quadruple therapy with optimized PPI
Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500MG QID, and Omeprazole 20 mg QID for 14 days.
Bismuth quadruple therapy with standard PPI
"Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500mg QID, and Omeprazole 20mg (active BID + placebo BID) for 14 days.~\*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding"
Clarithromycin triple therapy with optimized PPI
Amoxicillin 1000mg (active BID + placebo BID), Clarithromycin 500mg (active BID + placebo BID), and Omeprazole 20mg QID for 14 days. \*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding
Clarithromycin triple therapy with standard PPI
Amoxicillin 1000mg (active BID + placebo BID), Clarithromycin 500mg (active BID + placebo BID), and Omeprazole 20mg (active BID + placebo BID) for 14 days. \*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding
Standard bismuth quadruple therapy
Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500mg QID, and Omeprazole 20mg (active BID + placebo BID) for 14 days. \*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding
VA San Diego Healthcare System, San Diego, CA, San Diego
San Diego Veterans Healthcare System
FED
VA Office of Research and Development
FED